The U.S. Food and Drug Administration (FDA) announced Teva Pharmaceutical Industries is recalling one lot of its generic Parkinson’s combo drug carbidopa/levodopa because of concerns that it could contain too much of an active pharmaceutical ingredient.
The recall FDA labeled the recall as Class II status. Teva said the recall, which is nationwide, involved 3,881 bottles of carbidopa/levodopa 25 mg/100 mg. The company issued the recall out of precaution after stability testing found that the product might be super-potent, according to FiercePharmanufacturing.com. More Teva Recalling Parkinson’s Drug Due to Potency Concerns